JP2024086870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024086870A5 JP2024086870A5 JP2024063938A JP2024063938A JP2024086870A5 JP 2024086870 A5 JP2024086870 A5 JP 2024086870A5 JP 2024063938 A JP2024063938 A JP 2024063938A JP 2024063938 A JP2024063938 A JP 2024063938A JP 2024086870 A5 JP2024086870 A5 JP 2024086870A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cdr
- engineered
- tregs
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025097962A JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648684P | 2018-03-27 | 2018-03-27 | |
| US62/648,684 | 2018-03-27 | ||
| JP2021502704A JP2021531280A (ja) | 2018-03-27 | 2019-03-21 | 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 |
| PCT/US2019/023395 WO2019190879A1 (en) | 2018-03-27 | 2019-03-21 | Car-treg-based therapies for treating neurodegenerative diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502704A Division JP2021531280A (ja) | 2018-03-27 | 2019-03-21 | 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025097962A Division JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024086870A JP2024086870A (ja) | 2024-06-28 |
| JP2024086870A5 true JP2024086870A5 (enExample) | 2024-10-25 |
| JP7697096B2 JP7697096B2 (ja) | 2025-06-23 |
Family
ID=68060734
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502704A Pending JP2021531280A (ja) | 2018-03-27 | 2019-03-21 | 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 |
| JP2024063938A Active JP7697096B2 (ja) | 2018-03-27 | 2024-04-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
| JP2025097962A Pending JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502704A Pending JP2021531280A (ja) | 2018-03-27 | 2019-03-21 | 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025097962A Pending JP2025123315A (ja) | 2018-03-27 | 2025-06-11 | 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12173030B2 (enExample) |
| EP (1) | EP3773629A4 (enExample) |
| JP (3) | JP2021531280A (enExample) |
| KR (2) | KR102892999B1 (enExample) |
| CN (1) | CN112867496A (enExample) |
| AU (1) | AU2019242381B2 (enExample) |
| CA (1) | CA3095298A1 (enExample) |
| WO (1) | WO2019190879A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102892999B1 (ko) | 2018-03-27 | 2025-11-28 | 아즈테라피즈 인코포레이티드 | 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법 |
| CN116134144A (zh) | 2020-04-23 | 2023-05-16 | Az治疗股份有限公司 | 细胞的hla-i类mhc消融 |
| US20230210899A1 (en) * | 2020-05-28 | 2023-07-06 | Aztherapies, Inc. | CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases |
| CN117957246A (zh) * | 2021-09-03 | 2024-04-30 | 桑格摩生物治疗股份有限公司 | Mog结合蛋白和其用途 |
| WO2023047098A2 (en) * | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-p75ntr chimeric antigen receptor |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| CN118272314A (zh) * | 2024-04-15 | 2024-07-02 | 华中科技大学同济医学院附属同济医院 | 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007140971A2 (en) * | 2006-06-06 | 2007-12-13 | F. Hoffmann-La Roche Ag | Cell adhesion proteins as biomarker for alzheimer's disease |
| EP2046828A2 (en) | 2006-07-07 | 2009-04-15 | Wyeth | Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| US8790642B2 (en) * | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| SG10201602159VA (en) * | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| KR20140071277A (ko) * | 2011-05-19 | 2014-06-11 | 타이제닉스, 에스.에이.유. | 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도 |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| ES3051035T3 (en) | 2014-12-30 | 2025-12-23 | The Brigham And Womens Hospital Inc | Methods to improve cell therapy |
| WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| MX393951B (es) * | 2015-04-07 | 2025-03-24 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| CN111357090B (zh) * | 2017-11-11 | 2024-01-05 | 微材料有限责任公司 | 用于高压处理腔室的气体输送系统 |
| KR102892999B1 (ko) | 2018-03-27 | 2025-11-28 | 아즈테라피즈 인코포레이티드 | 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법 |
| US20230210899A1 (en) | 2020-05-28 | 2023-07-06 | Aztherapies, Inc. | CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases |
-
2019
- 2019-03-21 KR KR1020207030758A patent/KR102892999B1/ko active Active
- 2019-03-21 JP JP2021502704A patent/JP2021531280A/ja active Pending
- 2019-03-21 US US17/041,835 patent/US12173030B2/en active Active
- 2019-03-21 CA CA3095298A patent/CA3095298A1/en active Pending
- 2019-03-21 AU AU2019242381A patent/AU2019242381B2/en active Active
- 2019-03-21 CN CN201980035934.XA patent/CN112867496A/zh active Pending
- 2019-03-21 EP EP19776538.1A patent/EP3773629A4/en active Pending
- 2019-03-21 WO PCT/US2019/023395 patent/WO2019190879A1/en not_active Ceased
- 2019-03-21 KR KR1020257039577A patent/KR20250174989A/ko active Pending
-
2024
- 2024-04-11 JP JP2024063938A patent/JP7697096B2/ja active Active
- 2024-11-01 US US18/934,745 patent/US20250129158A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097962A patent/JP2025123315A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024086870A5 (enExample) | ||
| JP2021501162A5 (enExample) | ||
| JP2024056687A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2021191763A5 (enExample) | ||
| JP2023123726A5 (enExample) | ||
| RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
| JP2009225799A5 (enExample) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2023134618A5 (enExample) | ||
| RU2018146158A (ru) | Антитела | |
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2020037555A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| RU2017121327A (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| JP2016512551A5 (enExample) | ||
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| JP2016505546A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2012530496A5 (enExample) | ||
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| HRP20241013T1 (hr) | Protutijela za kelatirane radionuklide |